Glaukos Received the US FDA’s Approval for iDose TR (travoprost intracameral implant) for Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Patients
Shots:
- The approval was based on the results from 2 P-III trials incl. (GC-010) & (GC-012) evaluating the safety & efficacy of iDose TR (75 mcg) models with varying travoprost release rates vs topical timolol ophthalmic solution (0.5%, BID) in lowering IOP in patients (n=1,150) suffering from OHT or OAG
- In both trials, 98% vs 95% of patients continued evaluation, and 81% of iDose TR patients were fully free of topical medicines that lower IOP at 12mos. The approval was also supported by the P-IIb study results that depicted a reduction in topical IOP-lowering for up to 36mos.
- Glaukos expects to initiate the commercial launch activities for iDose TR by Q1’24 & has established a wholesale acquisition cost of $13,950/dose or implant
Ref: Glaukos | Image: Glaukos
Related News:- Stuart Therapeutics Entered into an Exclusive License Agreement with Glaukos Corporation to Develop the First Neuroprotective Therapy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
